바이오인

Europe is a leading player in the establishment of a radical reinterpretation of our approach to healthcare known as personalised medicine. As a result of previous European investment in research infrastructure, many of the most valuable tools employed to lay the foundations for this approach are located within Europe. Continued investment will nevertheless be required to fully exploit this key European competitive advantage. In this position paper, the chairs of the scientific committee responsible for the recently established ESF Forward Look Personalised Medicine for the European Citizen (iPM) highlight those areas in which the new EU strategic Framework Programme (FP8) can play a key role in supporting these developments.